New: Introducing the Finviz Futures Map

Longeveron

Contributing Author

Recent Articles by Longeveron

Aug-20	Longeveron to Present at the H.C. Wainwright 27th Annual Global Investment Conference LGVN GlobeNewswire
Aug-13	Longeveron Announces Second Quarter 2025 Financial Results and Provides Business Update LGVN GlobeNewswire
Aug-11	Longeveron Announces Closing Of Up To $17.5 Million Public Offering LGVN GlobeNewswire
Aug-08	Longeveron Announces Up To $17.5 Million Public Offering LGVN GlobeNewswire
Aug-05	Longeveron to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 LGVN GlobeNewswire
Jul-21	Longeveron Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease LGVN GlobeNewswire
Jul-08	Longeveron Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) LGVN GlobeNewswire
Jun-26	Longeveron Appoints Than Powell as Chief Business Officer LGVN GlobeNewswire
Jun-24	Longeveron Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS) LGVN GlobeNewswire
Jun-09	Longeveron to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference LGVN GlobeNewswire
May-20	Longeveron to Attend BIO International Convention 2025 LGVN GlobeNewswire
May-12	Longeveron Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient LGVN GlobeNewswire
May-08	Longeveron Announces First Quarter 2025 Financial Results and Provides Business Update LGVN GlobeNewswire
May-02	Longeveron to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 LGVN GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.